To modulate or to skip: de-escalating PARP inhibitor maintenance therapy in ovarian cancer using adaptive therapy
Toxicity and emerging drug resistance pose important challenges in poly-adenosine ribose polymerase inhibitor (PARPi) maintenance therapy of ovarian cancer. We propose that adaptive therapy, which dynamically reduces treatment based on the tumor dynamics, might alleviate both issues. Utilizing in vi...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Cell Press
2024
|